2016
Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis
Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, Stubbs B, Vancampfort D, De Hert M, Olfson M, Kahl KG, Martin A, Guo JJ, Lane HY, Sung FC, Liao CH, Arango C, Correll CU. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry 2016, 73: 247. PMID: 26792761, DOI: 10.1001/jamapsychiatry.2015.2923.Peer-Reviewed Original ResearchConceptsIncidence rate ratiosT2DM riskHealthy controlsCoprimary outcomesT2DM incidencePsychiatric controlsIncidence rateType 2 diabetes mellitus riskMain modifiable risk factorsMultivariable meta-regression analysisSecond-generation antipsychotic prescriptionsCardiometabolic adverse effectsExposure-adjusted incidenceT2DM incidence rateModifiable risk factorsDiabetes mellitus riskStudy-level dataAntipsychotic-treated youthSystematic literature searchMeta-regression analysisOlanzapine prescriptionOlanzapine treatmentSecondary outcomesT2DM developmentAntipsychotic prescriptions
2002
Effects of Development on Olanzapine-Associated Adverse Events
WOODS SW, MARTIN A, SPECTOR SG, MCGLASHAN TH. Effects of Development on Olanzapine-Associated Adverse Events. Journal Of The American Academy Of Child & Adolescent Psychiatry 2002, 41: 1439-1446. PMID: 12447030, DOI: 10.1097/00004583-200212000-00015.Peer-Reviewed Original ResearchConceptsLiver function abnormalitiesAdverse eventsFunction abnormalitiesAtypical antipsychoticsComplaint riskWeight gainAtypical antipsychotic medicationsExtrapyramidal syndromeTardive dyskinesiaProlactin increaseAntipsychotic medicationAdolescent patientsRisk ratioPatient exposureSurveillance databaseAge groupsOlanzapineComplaintsConfidence intervalsExposure estimatesAntipsychoticsSedationPatientsChildrenAdults